|
π
|
Rapid assessment of SARS-CoV-2βevolved variants using virus-like particles
11 auth.
A. Syed,
T. Y. Taha,
M. Khalid,
T. Tabata,
I. Chen,
B. Sreekumar,
...
Pei-Yi Chen,
J. Hayashi,
K. Soczek,
M. Ott,
J. Doudna
|
7 |
2021 |
7
π
|
|
π
|
Limited cross-variant immunity from SARS-CoV-2 Omicron without vaccination
43 auth.
R. Suryawanshi,
I. Chen,
Tongcui Ma,
A. Syed,
N. Brazer,
P. Saldhi,
C. Simoneau,
A. Ciling,
M. Khalid,
B. Sreekumar,
P. Chen,
G. R. Kumar,
M. MontaΓ±o,
Ronne Gascon,
C. Tsou,
...
M. Garcia-Knight,
A. Sotomayor-GonzΓ‘lez,
V. Servellita,
A. Gliwa,
Jenny Nguyen,
I. Silva,
B. Milbes,
N. Kojima,
V. Hess,
M. Shacreaw,
L. Lopez,
M. Brobeck,
F. Turner,
F. Soveg,
A. George,
Xiaohui Fang,
M. Maishan,
Michael Matthay,
M. Morris,
D. Wadford,
C. Hanson,
W. Greene,
R. Andino,
L. Spraggon,
N. Roan,
C. Chiu,
J. Doudna,
M. Ott
|
7 |
2022 |
7
π
|
|
π
|
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
21 auth.
A. Syed,
A. Ciling,
T. Y. Taha,
I. Chen,
M. Khalid,
B. Sreekumar,
Pei-Yi Chen,
G. R. Kumar,
Rahul P. Suryawanshi,
I. Silva,
...
B. Milbes,
N. Kojima,
V. Hess,
M. Shacreaw,
L. Lopez,
M. Brobeck,
F. Turner,
L. Spraggon,
T. Tabata,
M. Ott,
J. Doudna
|
6 |
2021 |
6
π
|
|
π
|
Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles
21 auth.
A. Syed,
A. Ciling,
T. Y. Taha,
I. Chen,
M. Khalid,
B. Sreekumar,
P. Chen,
G. R. Kumar,
Rahul P. Suryawanshi,
I. Silva,
...
B. Milbes,
N. Kojima,
V. Hess,
M. Shacreaw,
L. Lopez,
M. Brobeck,
F. Turner,
L. Spraggon,
T. Tabata,
M. Ott,
J. Doudna
|
6 |
2022 |
6
π
|
|
π
|
Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination
41 auth.
R. Suryawanshi,
I. Chen,
T. Ma,
A. M. Syed,
C. Simoneau,
A. Ciling,
M. Khalid,
B. Sreekumar,
P.-Y. Chen,
A. George,
G. R. Kumar,
M. Montano,
M. Garcia-Knight,
N. Brazer,
P. Saldhi,
...
A. Sotomayor-GonzΓ‘lez,
V. Servellita,
A. Gliwa,
J. Nguyen,
I. Silva,
B. Milbes,
N. Kojima,
V. Hess,
M. Shacreaw,
L. Lopez,
M. Brobeck,
F. Turner,
F. Soveg,
X. Fang,
M. Maishan,
M. Matthay,
M. Morris,
D. Wadford,
C. Hanson,
W. Greene,
R. Andino,
L. Spraggon,
N. Roan,
C. Chiu,
J. Doudna,
M. Ott
|
5 |
2022 |
5
π
|
|
π
|
Rapid assembly of SARS-CoV-2 genomes reveals attenuation of the Omicron BA.1 variant through NSP6
19 auth.
T. Y. Taha,
I. Chen,
J. Hayashi,
T. Tabata,
Keith Walcott,
Gabriella R Kimmerly,
A. Syed,
A. Ciling,
R. Suryawanshi,
Hannah S Martin,
...
Bryan H Bach,
C. Tsou,
M. MontaΓ±o,
M. Khalid,
B. Sreekumar,
G. Renuka Kumar,
S. Wyman,
J. Doudna,
M. Ott
|
4 |
2023 |
4
π
|
|
π
|
FOXO1 promotes HIV Latency by suppressing ER stress in T cells
17 auth.
Albert Vallejo-Gracia,
I. Chen,
Rosalba Perrone,
E. Besnard,
D. Boehm,
E. Battivelli,
T. Tezil,
Karsten Krey,
K. Raymond,
Philip A Hull,
...
Marius Walter,
Ireneusz B. Habrylo,
A. Cruz,
S. Deeks,
S. Pillai,
E. Verdin,
M. Ott
|
4 |
2020 |
4
π
|
|
π¦
|
Viral E Protein Neutralizes BET Protein-Mediated Post-Entry Antagonism of SARS-CoV-2
20 auth.
I. Chen,
James E. Longbotham,
Sarah McMahon,
R. Suryawanshi,
Jared Carlson-Stevermer,
Meghna Gupta,
Meng Yao Zhang,
F. Soveg,
J. Hayashi,
T. Y. Taha,
...
V. Lam,
Yang Li,
Zanlin Yu,
E. Titus,
Amy Diallo,
Jennifer Oki,
K. Holden,
N. Krogan,
Danica GaloniΔ Fujimori,
M. Ott
|
4 |
2021 |
4
π¦
|
|
π
|
Mild SARS-CoV-2 infection results in long-lasting microbiota instability
16 auth.
V. Upadhyay,
Rahul P. Suryawanshi,
P. Tasoff,
Maria McCavitt-Malvido,
Renuka Kumar,
Victoria W. Murray,
Cecilia Noecker,
J. Bisanz,
Y. Hswen,
C. Ha,
...
B. Sreekumar,
I. Chen,
S. Lynch,
M. Ott,
Sulggi A. Lee,
P. Turnbaugh
|
4 |
2022 |
4
π
|
